(2R,3R/2S,3S)-1-[N-(TERT.-BUTOXYCARBONYL)-(S)-PHENYLALANYL]-AZIRIDINE-2,3-DICARBOXYLIC-ACID
Compound with spectra: 1 NMR
![(2R,3R/2S,3S)-1-[N-(TERT.-BUTOXYCARBONYL)-(S)-PHENYLALANYL]-AZIRIDINE-2,3-DICARBOXYLIC-ACID](/api/compound/I1hUON7QtoE.png?ph=true&h=300&w=458 "(2R,3R/2S,3S)-1-[N-(TERT.-BUTOXYCARBONYL)-(S)-PHENYLALANYL]-AZIRIDINE-2,3-DICARBOXYLIC-ACID")
| SpectraBase Compound ID | I1hUON7QtoE |
|---|---|
| InChI | InChI=1S/2C18H22N2O7/c2*1-18(2,3)27-17(26)19-11(9-10-7-5-4-6-8-10)14(21)20-12(15(22)23)13(20)16(24)25/h2*4-8,11-13H,9H2,1-3H3,(H,19,26)(H,22,23)(H,24,25)/t2*11?,12-,13-/m10/s1 |
| InChIKey | CAZNBHMKWQGHRF-JMOFKJLBSA-N |
| Mol Weight | 756.76 g/mol |
| Molecular Formula | C36H44N4O14 |
| Exact Mass | 756.285402 g/mol |
| Enantiomer InChIKey | CAZNBHMKWQGHRF-REQDMKMESA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CDCl3 |
N-[N-(TERT.-BUTOXYCARBONYL)-L-PHENYLALANYL-L-SERYL]-O-TERT.-BUTYL-L-VALIN
(2R,3R/2S,3S)-1-[N-(TERT.-BUTOXYCARBONYL)-(S)-LEUCYL-GLYCYL]-3-ETHOXYCARBONYL-AZIRIDINE-2-CARBOXYLIC-ACID
N-[N-(TERT.-BUTOXYCARBONYL)-L-PHENYLALANYL-(BETA-O-ACETYL)-L-SERYL]-O-TERT.-BUTYL-L-ALANIN
N-(3,4,4-trimethyl-1,2-dioxethane-3-ylmethoxycarbonyl)-L-phenylalanyl-L-leucine
N-[N-(TERT.-BUTOXYCARBONYL)-L-PHENYLALANYL-ALPHA,BETA-DIDEHYDRO-ALANYL]-O-TERT.-BUTYL-L-VALIN
pentanoic acid, 5-amino-4-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-[4-(phenylmethoxy)phenyl]propyl]amino]-5-oxo-, phenylmethyl ester
METHYL-N-(BENZYLOXYCARBONYL)-PHENYLALANYLLEUCYLLEUCINE
METHYL-N-(BENZYLOXYCARBONYL)-PHENYLALANYLVALYLVALINE
CBZ-PHE-O-BENZYL-THR
TERT.-BUTYLOXYCARBONYL-L-LEUCYL-L-PROLYL-METHYLESTER
| Title | Journal or Book | Year |
|---|---|---|
| aziridinyl peptides as inhibitors of cysteine proteases: Effect of a free carboxylic acid function on inhibition | Bioorganic & Medicinal Chemistry | 2000 |